Pilot Study: AI Algorithm for Dermatology Referral Optimization
NCT ID: NCT06228014
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2022-11-23
2025-05-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary care physician will explain to the patient what his/her participation in the study will consist of by means of the Patient Information Sheet. The patient, in turn, will be able to ask all the questions he/she considers appropriate in order to clarify all his/her doubts regarding the study. If the patient wishes to participate in the study, he/she will sign the Informed Consent Form and will be assigned a study code. After signing the informed consent, the data collection process begins. The Principal Investigator and/or collaborating investigators assigned to this task will collect demographic data (age, sex) and data related to the diagnosis, characteristics and treatment of the pathology.
Primary care physicians should take photographs showing the areas affected by the pathology. These photographs will be taken with their own smartphone or using a mobile dermatoscope if the use of a mobile dermatoscope is clinically relevant. The primary care physician, will record the photographs periodically, uploading the images to a Google Drive folder that the study sponsor will enable at the beginning of the study. The photographs are named using a code that includes the patient ID (NNN) and photograph number (nn).
Primary care physicians will assess the patient\'s pathology as they would in a routine consultation and record their diagnosis and referral criteria, and associate them with the patient\'s photographs and demographic data to be collected by the research team telematically at the end of the study duration.
These information transfers and the storage of the photographs will be in line with the European Regulation 2016/679 of 27 April on the protection of natural persons with regard to the processing of personal data and the free movement of such data and the Organic Law 3/2018 of 5 December on the Protection of Personal Data and guarantee of digital rights.
The specialist physicians will have a period of one month after the end of the recruitment period to evaluate and label the photographs taken. In this labeling process they will record their diagnosis, and whether they consider that the referral has been appropriate or not. This information will be collected by the research team telematically at the end of the study duration.
This transfer of information and storage of the photographs will comply with European Regulation 2016/679, of 27 April, on the protection of natural persons with regard to the processing of personal data and the free movement of such data and with Organic Law 3/2018, of 5 December, on the Protection of Personal Data and guarantee of digital rights.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Workflow Optimization Using Artificial Intelligence for Dermatological Conditions
NCT06263413
UV Sensor in Patients With Actinic Keratosis
NCT05481073
Development and Validation of a Quality of Life Instrument for Actinic Keratosis
NCT01444989
Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne
NCT01591304
An Open-Label Safety Study of A-101 Solution
NCT02667288
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Many studies show discrepancies in opinion between the opinions of primary care physicians and dermatologists, with percentages of agreement in their diagnoses ranging from 57% to 65.52% depending on the study. In general, primary care physicians do not demonstrate adequate knowledge of skin diseases, their diagnosis and treatments.
This human limitation when evaluating skin diseases is also reflected in the effort and time required to estimate the degree of involvement of a patient or the stage of the pathology. So much so, that it ends up being a very unrewarding task and can lead to poor adherence to the protocol and inadequate referrals.
Time consumption is of particular concern given that the number of medical professionals, especially in dermatology, is not sufficient in relation to the demand that exists. Access of the general population to a dermatology specialist is complicated, due to the low number (3 dermatologists per 100,000 inhabitants), making it even more difficult in small population centers. Because of this, screening for dermatologic lesions should be performed by the primary care physician, whose diagnostic capacity is even lower and can increase the risk of misdiagnosis.
In this regard, the literature shows a discordance of 55% to 65% between the primary care physician and the specialist6 and studies confirm a number of expected features: common dermatological diseases are often unrecognized or misdiagnosed by non-dermatologists, due to the particular profiles of common diagnoses in this activity (drug-induced rash, fungal infections).
And in addition to these inherent limitations, in cases where the preliminary examination is performed by the patient, the possibility of bias is added. This is especially true in cases where the patient knows that the treatment he or she receives will be determined by the information he or she provides. In addition, the medical team lacks the means to ensure that the values reported by the patient are true, which precludes external verification.
Fortunately, in recent years there has been an increasing demand to develop Computer Aided Diagnosis (CAD) systems and other systems that facilitate the detection of different pathologies through algorithms. CAD systems are an interdisciplinary technology that combines artificial intelligence and digital image processing. Image processing based on complex pattern recognition systems makes it possible for the physician to interpret the information contained in the medical image with much less difficulty. Advances in image recognition and artificial intelligence have led to innovations in the diagnosis of all types of pathologies. It has been demonstrated that through artificial intelligence (AI) algorithms it is possible to classify photographs of lesions with a level of competence comparable to that of a medical expert.
Therefore, the use of artificial vision applications when gathering information about the patient\'s condition presents a huge advance that not only brings reliability to the documentation process, but also allows greater precision when measuring visual signs of the pathology, and consequently, informs the criteria for referral to the specialist.
Consequently, this study aims to clinically validate a novel artificial intelligence tool for activity grading in affected patients.
This innovation has the potential to facilitate medical practice in the diagnosis of skin cancer and improve the quality of life of patients affected by this pathology. In addition, this technology provides a new measurement tool that opens the door to a new field of research into the efficacy of treatments or the analysis of the pathology itself and its subtypes.
The hypothesis guiding this study is that artificial intelligence algorithms developed by AI LABS GROUP SL significantly optimize the appropriateness of dermatology referrals.
The main objective of this study is to validate that the artificial intelligence algorithms developed by AI LABS GROUP SL optimize the appropriateness of referrals to dermatology. That is, to reduce the number of mild or benign cases that are referred to the dermatologist, since they can be managed from primary care.
This is an analytical prospective observational study of a series of clinical cases. It is a longitudinal study.
This study estimates a recruitment period of 2 months. The specialist physicians will have 1 month to label the photographs. The investigators will have 1 month to close and edit the database, analyze the data, and prepare the final report of the study.
The total duration of the study is estimated at 4 months.
\"proof-of-concept\" pilot study in which the sample size has been estimated based on the number of patients with a diagnosis of skin diseases that can be seen in four primary care services of Hospital Universitario de Cruces. During the recruitment period of the study, all patients with a diagnosis of skin diseases who meet the selection criteria will be included. The data collected from these patients during the study period will be analyzed, and depending on the results obtained, it will be assessed whether it is necessary to expand the sample size to include more patients.
The main variable aims to determine the efficiency of the algorithm in optimizing the appropriateness of dermatology referrals.
To this end, the researchers will identify inappropriate referrals. The investigators define an inappropriate referral as one that, according to the criteria of the specialists consulted in the study, does not require the attention of a dermatologist in order to be treated, as may be the case of seborrheic keratosis. For this purpose, a photograph will be taken and the date of the patient\'s visit to the clinic and the criteria for moving to the next stage of the care process will be recorded. That is to say: the date of the visit attended by the primary care physician and whether or not it resulted in a referral to a dermatologist, as well as the referral criterion used, will be recorded. In addition, a photograph of the area affected by the pathology will be taken at this step. Later, the Principal Investigators will evaluate the photos and determine whether the referral was appropriate or not.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with any kind of skin pathologies
Adult patients (≥ 18 years) with skin pathologies seen in the primary care service of health centers referring to Cruces and Basurto University Hospitals. Patients participating in this study did not receive any specific treatment as part of the research protocol. Patients continued their regular prescribed medications and treatments as directed by their primary healthcare providers. No additional medications or treatments were administered as part of this study.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18 years or older.
* Patients who have signed the informed consent for the study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Osakidetza
OTHER
Servicio Vasco de Salud Osakidetza, Spain
UNKNOWN
Hospital de Cruces
OTHER
AI Labs Group S.L
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Cruces
Barakaldo, Biscay, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PS2022074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.